LEONABIO INC (LONA) Stock Price & Overview
NASDAQ:LONA • US04746L2034
Current stock price
The current stock price of LONA is 9.22 USD. Today LONA is down by -1.71%. In the past month the price decreased by -1.6%.
LONA Key Statistics
- Market Cap
- 86.576M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -9.24
- Dividend Yield
- N/A
LONA Stock Performance
LONA Stock Chart
LONA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to LONA.
LONA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LONA. While LONA seems to be doing ok healthwise, there are quite some concerns on its profitability.
LONA Earnings
LONA Forecast & Estimates
9 analysts have analysed LONA and the average price target is 16.32 USD. This implies a price increase of 77.01% is expected in the next year compared to the current price of 9.22.
LONA Groups
Sector & Classification
LONA Financial Highlights
Over the last trailing twelve months LONA reported a non-GAAP Earnings per Share(EPS) of -9.24. The EPS increased by 63.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -114.6% | ||
| ROE | -380.03% | ||
| Debt/Equity | 0 |
LONA Ownership
LONA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.83 | 853.191B | ||
| JNJ | JOHNSON & JOHNSON | 17.83 | 544.731B | ||
| MRK | MERCK & CO. INC. | 22.11 | 278.01B | ||
| PFE | PFIZER INC | 9.14 | 155.349B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.38 | 121.259B | ||
| ZTS | ZOETIS INC | 16.71 | 49.697B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.547B | ||
| VTRS | VIATRIS INC | 5.91 | 17.152B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.49 | 11.291B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.359B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.199B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.101B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.11 | 4.797B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LONA
Company Profile
LeonaBio, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. The company is headquartered in Bothell, Washington and currently employs 26 full-time employees. The company went IPO on 2020-09-18. The firm's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations.
Company Info
IPO: 2020-09-18
LEONABIO INC
18706 North Creek Parkway, Suite 104
Bothell WASHINGTON US
Employees: 26
Phone: 13026365400
LEONABIO INC / LONA FAQ
What does LEONABIO INC do?
LeonaBio, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. The company is headquartered in Bothell, Washington and currently employs 26 full-time employees. The company went IPO on 2020-09-18. The firm's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations.
What is the stock price of LEONABIO INC today?
The current stock price of LONA is 9.22 USD. The price decreased by -1.71% in the last trading session.
What is the dividend status of LEONABIO INC?
LONA does not pay a dividend.
How is the ChartMill rating for LEONABIO INC?
LONA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is LEONABIO INC (LONA) stock traded?
LONA stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for LONA stock?
LEONABIO INC (LONA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.24).
What is the ownership structure of LEONABIO INC (LONA)?
You can find the ownership structure of LEONABIO INC (LONA) on the Ownership tab.